Cryoablation with immunotherapy for liver cancer that progressed after PD-1 treatment
Part of Cancer, Digestive system clinical trials.
This trial tests adding cryoablation (freezing tumors) to an immunotherapy combination (PD-1 antibody and bevacizumab) for people with liver cancer whose disease got worse after prior PD-1 therapy. The goal is to see if this approach can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old and expected to live at least 3 months.
- You have primary liver cancer (hepatocellular carcinoma) that got worse after treatment with a PD-1 or PD-L1 antibody.
- Your liver function must be good (Child-Pugh score A or B, less than 7).
- You must have at least one tumor that can be measured by a special scan (mRECIST).
- You must be able to walk and care for yourself (ECOG score 0 or 1).
- You cannot have other serious health problems like severe kidney, heart, or lung disease, or active bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
This trial tests a combination of tumor freezing (cryoablation), an experimental immunotherapy (SHR-1701), and a targeted therapy pill (famitinib) for people with advanced bile duct cancer that has not responded to standard treatment.
Hear when a new Carcinoma, Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.